AstraZeneca PLC (ZEG.SG)
- Business Wire
IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
WILMINGTON, Del., June 25, 2024--Positive high-level results from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (EFS) and the key secondary endpoint of overall survival (OS) versus neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer (MIBC). Patients were treated with IMFINZI in combination wit
- Simply Wall St.
Admiral Group And Two Other UK Exchange Stocks Estimated As Undervalued For Investment Consideration
The United Kingdom's financial markets are currently poised at a critical juncture, with the FTSE 100's movements closely tied to the upcoming release of May's inflation data and decisions from the Bank of England. Amid these market conditions, identifying undervalued stocks can offer investors potential opportunities for growth in a fluctuating economic environment.
- Simply Wall St.
One AstraZeneca Insider Raised Stake By 50% In Previous Year
Viewing insider transactions for AstraZeneca PLC's ( LON:AZN ) over the last year, we see that insiders were net...
